Italy-based Resalis Therapeutics has closed a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors. The company intends to use the proceeds to initiate and complete the first-in-human Phase I clinical trial and reach Phase II readiness for its lead program, RES-010, in obesity. RES-010 […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!